SAN DIEGO—A hormone secreted by the parathyroid gland is both a builder and a destroyer of bone in humans, with important implications for a variety of conditions treated by rheumatologists. In the Oscar Gluck, MD, Memorial Lecture at the 2017 ACR/ARHP Annual Meeting Nov. 3–8, Henry Kronenberg, MD, chief of the Endocrine Division at Massachusetts…
New research in mice shows that sclerostin deficiency may play a significant role in bone formation, possibly despite skeletal age. In the study, sclerostin-deficient mice more readily formed cortical bone and had increases in periosteal bone formation rates, as well as increased expression of the Wnt inhibitor Dkk1, than controls…
NEW YORK (Reuters Health)—The early elevation in intact parathyroid hormone (iPTH) seen with denosumab treatment is not associated with increased bone formation, according to research from Eli Lilly and Company. Denosumab is a member of the anticatabolic/antiresorptive class of drugs used to treat osteoporosis; iPTH levels are increased in the first several months after denosumab…
Working both to support bone formation and suppress it, a new study reveals orexin neuropeptides are essential regulators of skeletal homeostasis
New research reports on the increased sensitivity of human-HLA-B27 transgenic rat bone marrow monocytes to TNF-α stimulation and osteoclast differentiation. (posted June 27, 2013)
Studies look at how the balance between osteoclast-mediated bone resorption and osteoblast mediated bone formation is undermined in people with arthritic conditions